Citigroup
LTRN icon

Citigroup’s Lantern Pharma LTRN Stock Holding History

Citigroup’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45
Closed -$62 – 6035
2026
Q1 		$62 Buy
+45
New +$126 ﹤0.01% 5631

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Citigroup's LTRN Position: Q2 2026 in Review

Citigroup sold out of Lantern Pharma (LTRN) in Q2 2026, closing a stake of 45 shares — an estimated $62 sold.

Citigroup first reported a position in LTRN in Q1 2026 and held it in 1 quarter. The position peaked at $62 in Q1 2026. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Citigroup reported no remaining Lantern Pharma position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 45 Lantern Pharma shares in Q2 2026, an estimated $62.
  • Citigroup first reported a position in Lantern Pharma in Q1 2026 and held it in 1 quarter.
  • Citigroup's Lantern Pharma position peaked at $62 in Q1 2026.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.